CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
02. Juni 2022 20:10 ET
|
Aptose Biosciences, Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 ...
Aptose Presents Highlights from Corporate Update and KOL Event
02. Juni 2022 17:30 ET
|
Aptose Biosciences, Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE...
Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd
12. Mai 2022 10:00 ET
|
Aptose Biosciences, Inc.
Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th at EHA2022 Hybrid Congress SAN DIEGO and TORONTO, May 12, 2022 (GLOBE NEWSWIRE) --...
Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
04. Mai 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Executive Management Changes
07. April 2022 07:00 ET
|
Aptose Biosciences, Inc.
─ Appoints Philippe Ledru as Chief Commercial Officer ─ ─ Announces resignation of CFO/CBO Jotin Marango, MD, PhD ─ SAN DIEGO and TORONTO, April 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences...
Aptose Reports Results for the Fourth Quarter and Full Year 2021
22. März 2022 16:01 ET
|
Aptose Biosciences, Inc.
- HM43239 clinical remission at 120mg expands list of potential treatable AML populations - - On track to initiate genotype-enriched expansion program for HM43239 in 2H22 - - Cash runway...
HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia
13. Dezember 2021 16:30 ET
|
Aptose Biosciences, Inc.
HM43239 Data Featured in Oral Presentation at the American Society of Hematology Annual Meeting Aptose Presents Highlights from Luxeptinib and APTO-253 and Provides Corporate Update SAN DIEGO,...
Aptose to Hold Corporate Update Monday, December 13th
29. November 2021 07:30 ET
|
Aptose Biosciences, Inc.
HM43239 clinical update in AML after oral presentation at 2021 ASH Annual MeetingLuxeptinib clinical update in AML and B-cell cancers SAN DIEGO and TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Aptose...